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Period (PER) proteins are essential components of
the mammalian circadian clock. They form com-
plexes with cryptochromes (CRY), which negatively
regulate CLOCK/BMAL1-dependent transactivation
of clock and clock-controlled genes. To define the
roles of mammalian CRY/PER complexes in the
circadian clock, we have determined the crystal
structure of a complex comprising the photolyase
homology region of mouse CRY1 (mCRY1) and a
C-terminal mouse PER2 (mPER2) fragment. mPER2
winds around the helical mCRY1 domain covering
the binding sites of FBXL3 and CLOCK/BMAL1,
but not the FAD binding pocket. Our structure
revealed an unexpected zinc ion in one interface,
which stabilizes mCRY1-mPER2 interactions in vivo.
We provide evidence that mCRY1/mPER2 complex
formation is modulated by an interplay of zinc
binding and mCRY1 disulfide bond formation, which
may be influenced by the redox state of the cell. Our
studies may allow for the development of circadian
and metabolic modulators.
INTRODUCTION
In mammals, many physiological, metabolic, and behavioral
processes are regulated in a daytime-dependent manner. Circa-
dian (24 hr) rhythms are generated by endogenous circadian
clocks, which are operated by interconnected transcriptional
and translational feedback loops (Young and Kay, 2001).
Additionally, the cellular redox state plays an essential role in
circadian clock regulation and links the clock to the cell’s
metabolic state (Eckel-Mahan and Sassone-Corsi, 2009). In
anucleate human red blood cells, several circadian oxidation
rhythms have been described, including cysteine oxidationcycles in the H2O2 scavenging peroxiredoxins, the daily rhythmic
transition between dimeric (mostly oxidized) and tetrameric
(mostly reduced) hemoglobin, and daily nicotinamide adenine
dinucleotide (NADH)/nicotinamide adenine dinucleotide phos-
phate (NADPH) oscillations (O’Neill and Reddy, 2011). Further-
more, circadian cycles of peroxiredoxin oxidation occur in all
kingdoms of life and are interconnected with the circadian
gene-regulatory transcriptional feedback loops in DNA-contain-
ing cells (Edgar et al., 2012; O’Neill and Reddy, 2011; O’Neill
et al., 2011).
In the canonical gene-regulatory feedback loop of the
mammalian circadian clock, the basic helix-loop-helix (bHLH)-
PAS (PER-ARNT-SIM) transcription factors BMAL1 and CLOCK
activate the transcription of three period (Per1, 2, and 3) and two
cryptochrome (Cry1 and 2) clock genes. CRY proteins repress
the transcriptional activity of the CLOCK/BMAL1 complex
toward the Cry and Per genes (Griffin et al., 1999; Kume et al.,
1999; van der Horst et al., 1999), as well as a large number of
clock-controlled genes regulating circadian physiology (Koike
et al., 2012). Additionally, CRYs are involved in the regulation
of glucose homeostasis, insulin secretion, and tissue-specific
insulin sensitivity (Barclay et al., 2013; Lamia et al., 2011; Zhang
et al., 2010).
The CRY repressor activity is determined by posttranslational
modifications, as well as the daily rhythmic synthesis, nuclear
translocation, and degradation of CRYs, which are controlled
by interactions with PER1/2 (Yagita et al., 2002) and with the
E3 ligase components FBXL3 (Gatfield and Schibler, 2007) and
FBXL21 (Hirano et al., 2013; Yoo et al., 2013). The CRY tails
and the most C-terminal helix (a22) of the cryptochrome photo-
lyase homology region (PHR) (Figure 1A) are involved in tran-
scriptional repression of CLOCK/BMAL1 (Chaves et al., 2006)
and BMAL1 binding (Czarna et al., 2011). The PHR interacts
with C-terminal regions of PER1 and PER2 (Eide et al., 2002;
Miyazaki et al., 2001; Ozber et al., 2010; Tomita et al., 2010;
Yagita et al., 2002), with FBXL3 (Lamia et al., 2009; Xing et al.,
2013), FBXL21 (Hirano et al., 2013; Yoo et al., 2013) and with
the PAS domains of CLOCK (Huang et al., 2012).Cell 157, 1203–1215, May 22, 2014 ª2014 Elsevier Inc. 1203
Figure 1. Domain Architecture and Crystal Structure of mCRY1/mPER2 Heterodimer
(A) Domain architecture of mouse CRY1 and PER2. Two PAS domains (PAS-A and PAS-B) and the CK1ε/d- and CRY-binding regions of mPER2 are shown.
mCRY1 comprises a PHR, including helix a22 and a nonconserved C-terminal tail. Dashed lines indicate crystallized fragments.
(B) Ribbon presentation of mCRY1[1–496] (PHR; cyan) in complex with mPER2[1132–1252] (yellow). Green, linker connecting the a/b- and a-helical domain of the
mCRY1-PHR. Brown, zinc ion at the mCRY1-mPER2 interface. Red line, C-terminal lid of mCRY1.
See also Figures S1 and S2 and Table S1.Phosphorylation of Ser71 by AMP kinase (AMPK) in response
to the cell’s metabolic state reduces CRY1 stability by enhancing
FBXL3 binding and weakening PER2 binding (Lamia et al., 2009).
Furthermore, PER2 is reported to compete for CRY1 binding to
the CLOCK/BMAL1-E-box complex (Ye et al., 2011). These
data suggest that PER2 might have overlapping CRY1-binding
sites with FBXL3 and CLOCK/BMAL1, which play a role in the
regulation of CRY1 stability and transcriptional repression
activity. Indeed, our mouse CRY1 (mCRY1) crystal structure
revealed partly overlapping mCRY1 regions that are involved in
mPER2 and FBXL3 interactions, as well as transcriptional
repression activities of mCRY1 (Czarna et al., 2013). Consistent
with our structure-based mutational analyses (Czarna et al.,
2013), the mCRY2/FBXL3/SKP1 complex structure (Xing et al.,
2013) showed that FBXL3 interacts with the flavin adenine dinu-
cleotide (FAD)-binding pocket, the C-terminal helix a22, and the
C-terminal lid of the mCRY-PHR. Moreover, competition with
mPER2 or FAD disrupts a preformed mCRY2/FBXL3 complex1204 Cell 157, 1203–1215, May 22, 2014 ª2014 Elsevier Inc.(Xing et al., 2013), and a period-lengthening small-molecule
compound that competes with FAD binding stabilizes mCRY1
by inhibiting ubiquitination (Hirota et al., 2012).
Here, we have determined the crystal structure of the complex
between the mCRY1-PHR and a C-terminal mPER2 fragment
in order to (1) provide further insights into how alternative binding
of mPER2, FBXL3, mCLOCK/BMAL1, or FAD regulates mCRY1
stability and transcriptional repression activity and (2) to advance
the development of CRY-stabilizing compounds that affect clock
or clock-controlled metabolic functions. mPER2 winds around
mCRY1, covering extensive surface areas that significantly
overlap with the binding sites of FBXL3 and mCLOCK/BMAL1.
Interestingly, our complex structure revealed a jointly co-
ordinated zinc ion that critically stabilizes full-length mCRY1-
mPER2 interactions in mammalian cells. Our mutational
analyses suggest that (1) formation of the Cys412-Cys363 disul-
fide bond, which we observed in the apo-mCRY1 structure
(Czarna et al., 2013), weakens mCRY1-mPER2 interactions,
and (2) zinc facilitates formation of the reduced state of mCRY1
and stabilizes the mCRY1/mPER2 complex. The regulation of
mCRY1-mPER2 interactions by zinc binding and CRY disulfide
bond formation/reduction may provide a molecular link between
the circadian clock and the cell’s metabolic/oxidative state.
RESULTS
Crystal Structure of the Mouse CRYPTOCHROME1-
PERIOD2 Complex
Using limited proteolysis, we identified a stable mCRY1/mPER2
core complex comprising the mCRY1-PHR (residues 1 to 496)
and mPER2 residues 1132 to 1252 (Figures 1, S1, and S2
available online). We have determined its 2.45 A˚ crystal structure
using molecular replacement with apo-mCRY1 (PDB ID 4K0R
[Czarna et al., 2013]) as search model in combination with
experimental selenium single-wavelength anomalous dispersion
(Se-SAD) phasing (Table S1).
In our mCRY1/mPER2 complex structure, mCRY1 adopts the
typical cryptochrome/photolyase fold (Mu¨ller and Carell, 2009)
with an N-terminal a/b domain, a C-terminal a-helical domain,
and a connecting linker region (Figure 1). Superposition of
apo-mCRY1 and mCRY1/mPER2 reveals several differences
between the two mCRY1 structures, especially in the C-terminal
lid, which significantly alters its conformation (see below), the
antenna recognition loop, the phosphate-binding loop, the linker
region, and the C-terminal helix a22 (Figures S3A–S3D). The
other characteristic loops of the 6-4-photolyase/animal cryp-
tochrome family, i.e., the protrusion loop, the a5-a6 loop, and
the electron-rich sulfur loop (Hitomi et al., 2009) (Figure S2) do
not change significantly upon mPER2 binding.
mPER2 winds around the a-helical domain of mCRY1
(Figure 1B). The crystallized mPER2 fragment comprises five
a helices (a1–a5, Ile1138–Thr1198) and a short N-terminal anti-
parallel b sheet formed by residues 1132–1136 (b1) and part of
the cloning overhang of mPER2 (b0). Residues Gly1199 to
Glu1214 following helix a5 adopt a well-ordered loop structure.
The most C-terminal residues 1215–1252 of the crystallized
mPER2[1132–1252] fragment are not seen in the electron den-
sity due to conformational disorder (Figures 1, S1B, and S1C).
Our CD spectra of the mCRY1[1–496]/mPER2[1132–1252]
complex support the high helical content of mCRY1-bound
mPER2 in solution. CD spectra of apo-mPER2[1132–1252],
however, suggest that unbound mPER2 is significantly less
structured (Table S2).We therefore propose that mCRY1 binding
induces a-helical folding of the C-terminal mPER2 fragment.
The mCRY1/mPER2 Complex Is Stabilized by Four
Interfaces and a Zinc Ion
Several elements of the mCRY1-PHR are involved in mPER2
binding: the C-terminal helix a22 and its preceding connector
loop, the C-terminal lid, the sulfur loop, the loop connecting
helices a5 and a6, helix a12, and helix a15. Overall, the
mCRY1/mPER2 complex buries a 3221 A˚2 solvent-accessible
surface area.
Helix a22 constitutes a central component of the mCRY1-
mPER2 interface. It is embedded between mPER2 helix a3
and the loop region C-terminal to mPER2 a5 (‘‘C-terminal helixinterface’’; Figures 2A and S1A). Notably, Arg483 and Lys485
(mCRY1 a22) are involved in mPER2 binding and transcriptional
repression in mammalian cells (Ozber et al., 2010), as well as
in interactions with purified C-terminal mBMAL1 fragments
(Czarna et al., 2011). In apo- and mPER2-bound mCRY1,
Arg483 forms an intramolecular salt bridge with Asp321 (sulfur
loop), which likely contributes to positioning of a22 (Figure S3C).
In the mCRY1/mPER2 complex, Arg483 forms an additional salt
bridge to Asp1167 (mPER2 a3) (Figures 2A, right, and S3C).
Furthermore, Gln486 and Gln490 (a22) hydrogen bond to
Gln1168mPER2, and Gln486 also hydrogen bonds to the back-
bone of Leu1164mPER2 (Figure 2A, left). The sulfur loop further
stabilizes the position of mPER2 a3, mostly via hydrophobic in-
teractions of Pro319mCRY1 (Figures 2A, right, and S1A). On the
other side of mCRY1 a22, Lys485 forms a hydrophilic side-chain
interaction with Asp1206 and a backbone hydrogen bond with
Val1207 in the C-terminal mPER2 loop region (Figure 2A, left).
Notably, Cys1210 and Cys1213 in the C-terminal mPER2
loop region and mCRY1 residues Cys414 (lid) and His473
(a22) tetrahedrally coordinate a zinc ion (‘‘zinc interface’’; Fig-
ures 1B, 2B, S1A, and S4). An anomalous difference map calcu-
lated for positioning of the selenomethionines of mPER2 gave
first evidence for the zinc ion in the crystal (Figures S4A and
S4B). An X-ray fluorescence scan confirmed its presence (Fig-
ure S4C). Atomic absorption spectroscopy confirmed the pres-
ence of zinc in the mCRY1/mPER2 complex in solution, but not
in the single proteins due to their incomplete zinc-binding sites
(Figure S4D).
Another heterodimer interface is formed between mCRY1 a12
and mPER2 helices a1 and a2 (referred to as ‘‘mPER2(a1-2)-
mCRY1(a12) interface’’; Figures 2C and S1A). mPER2 a1
additionally contacts mCRY1 a15, whereas mPER2 a2 also
interfaces with Tyr466 to Met470 in the loop preceding mCRY1
a22. Trp1139 (mPER2 a1) contacts mCRY1 a12 and a15.
Lys329 (mCRY1 a12) hydrogen bonds to backbone oxygens of
Ile1149 to Tyr1153 (mPER2 a2) and Asn323 to the Tyr1153
side chain. The loop connecting mPER2 a1 and a2 winds tightly
around Ala328 of mCRY1 a12.
mPER2 a4, which is part of a 20 amino acid stretch (1179
to 1198) reported to be essential for mCRY1 binding in cell-
based assays (Tomita et al., 2010), packs against the C-terminal
lid (including Phe405) and the a5–a6 connector loop (including
Leu148 and Thr149) of mCRY1 (‘‘mPER2(a4)-cap interface’’;
Figures 2D and S1A). Leu148 makes hydrophobic interactions
with Leu1189 and Phe1181 of mPER2, whereas Thr149
hydrogen bonds to Glu1188 and (water mediated) to Glu1191
of mPER2 a4.
The mCRY C-Terminal Lid Adopts Variable
Conformations and Is Involved in Disulfide Bond
Formation and Zinc Coordination
The major difference between the apo-mCRY1 and mCRY1
complex structure manifests in the conformation of the C-termi-
nal lid. Although the side chains of residues Phe406 to Phe410
are disordered in the apo structure, the loop is well defined
and adopts a deviating orientation in the complex structure (Fig-
ure 3A). This is likely due to its packing against a4, a5, and the
C-terminal loop of mPER2 (Figures 1B, 2D, 3B, and S3D). TheCell 157, 1203–1215, May 22, 2014 ª2014 Elsevier Inc. 1205
Figure 2. Close-Up View of mCRY1-mPER2 Interfaces
Crucial interface residues are shown as atomic sticks. Mutated residues are highlighted in green (CRY) and orange (PER). Dashed lines indicate salt bridges and
hydrogen bonds. See Results and Figure S1A legend for a detailed description of the interactions.
(A) C-terminal helix (a22) interface, two orientations: mCRY1 a22 is clenched by mPER2 helix a3 and the loop connecting mPER2 a5 with the zinc binding motif.
(B) Zinc (Zn) interface: His473 (a22) and Cys414 (lid) of mCRY1 and Cys1210 and Cys1213 of mPER2 tetrahedrally coordinate a zinc ion. The disulfide bridge
between Cys363 and Cys412 (compare apo-mCRY1; Figures 3A and 3B) is broken. This figure directly connects to Figure 2A (left) (compare Thr1208 [A] and
Cys1210 [B]).
(C) mPER2(a1–2)-mCRY1(a12) interface: mPER2 helices a1 and a2 interact with mCRY1 helices a12 and a15 and with Tyr466-Met470 in the loop preceding a22.
(D) mPER2(a4)-cap interface: mPER2 helix a4 packs against Thr149 and Leu148 in the a5-a6 loop and the C-terminal lid of mCRY1.
See also Figures S1, S2, S3, and S4.apo-mCRY1 structure contains a disulfide bridge between
Cys363 and Cys412, which has the potential to be a redox-
dependent link to the FAD-binding pocket (Czarna et al., 2013).
Located in the immediate vicinity of the zinc interface, this disul-
fide bridge is broken in the complex structure (Figures 2B and 3).
Thereby, we hypothesize that the C-terminal lid gains a higher
flexibility for interaction with mPER2.
In apo-mCRY1, Phe405 is embedded in a hydrophobic pocket
of the mCRY1-PHR. In the mCRY1/mPER2 complex, however,
Phe406 occupies the hydrophobic pocket of apo-Phe405,
whereas Phe405 projects to the surface (Figure 3A) and embeds
into a huge hydrophobic pocket lined by PER and CRY residues
(Figures 2D, S1A, and S3D). The mPER2-bound lid conformation
is additionally stabilized by backbone hydrogen bonding of
Phe405 and Gln407 with His1193mPER2 (Figure 2D) and by
Phe410, which inserts into a hydrophobic pocket, including
His359 and Trp399 (Figure 3B).1206 Cell 157, 1203–1215, May 22, 2014 ª2014 Elsevier Inc.In apo- and FBXL3-bound mCRY2 (Xing et al., 2013), the lid
adopts yet another position than in apo- and mPER2-bound
mCRY1. Phe424 and Phe423 of mCRY2/FBXL3 (Figure 3C) and
apo-mCRY2 (data not shown) position just as the corresponding
Phe406 and Phe405 in apo-mCRY1. Phe428mCRY2 (correspond-
ing to Phe410mCRY1) is not embedded in the mCRY-PHR but is
turned away from the mCRY2 core and mediates interactions
with FBXL3. Interestingly, in both the apo-mCRY2- and the
mCRY2/FBXL3 complex structure, there is no disulfide bridge
between Cys381 and Cys430 (corresponding to Cys363 and
Cys412 in mCRY1) (Figures 3C, S3E, and S3F). Instead,
Cys430 forms an intermolecular disulfide bridge with Cys340 of
FBXL3 in the mCRY2/FBXL3 complex structure (Figure S3F).
The FAD-Binding Pocket of mCRY1
ThemCRY2/FBXL3/SKP1complex structure (Xinget al., 2013) re-
vealed that theC-terminal tail of FBXL3occupies theFAD-binding
Figure 3. C-Terminal Lid and FAD-Binding Pocket of the mCRY1/mPER2 Complex
(A–C) The C-terminal lid adopts varying conformations in apo-CRY1, the mCRY1/mPER2 complex, and mCRY2. See Results for detailed comparison.
(A) Superposed C-terminal lids of mPER2-bound mCRY1 (cyan, mPER2 not shown) and apo-mCRY1 (gray). Apo-mCRY1: Phe406 to Phe410 are built as alanine.
mPER2-bound mCRY1: Phe406 adopts the position of apo-Phe405 whereas Phe405 points away from the mCRY1-PHR. The Cys363-Cys412 disulfide bridge is
broken. The 2Fo-Fc electron density (1s level) of complex mCRY1 is shown in blue.
(B) Superposition of FAD-binding pocket, C-terminal lid, and zinc-interface of the mCRY1/mPER2 complex (cyan/yellow) with apo-mCRY1 (gray) and FAD from
the mCRY2/FAD complex (Xing et al., 2013) (red, taken from PDB ID 4I6G; mCRY2 protein not shown for clarity). Upon mPER2 binding, the C-terminal lid and its
Gln407 side chain reorient. Trp292 rotates such that it would interfere with FAD binding.
(C) Superposition of C-terminal lids of mPER2-bound mCRY1 (cyan, mPER2 not shown) and FBXL3-bound mCRY2 (green, FBXL3 not shown). The disulfide
bridge between Cys381 and Cys430 (corresponding to Cys363-Cys412 of apo-mCRY1) is not observed in mCRY2 (see also Figures S3E and S3F).
See also Figure S3.pocket of mCRY2. In our mCRY1/mPER2 complex structure,
however, the FAD-binding pocket is accessible, unoccupied,
and in a very similar conformation as in apo-mCRY1 (Fig-
ure 3B) and apo-mCRY2. Notably, the side chains of Gln289,
Trp292, and His355 adopt an introversive position, which would
interfere with FAD binding. mPER2 binding does not affect the
conformation of His355 and Gln289, but reorientation of Trp292
is required to allow for the positioning of Gln407 in the mPER2-
bound lid conformation. We therefore suggest that, although
mPER2 binding to mCRY1 may somewhat negatively affect FAD
binding by enforcing an unfavorable side-chain orientation of
Trp292, it neither requires nor fully excludes the presence of FAD.
Structural Basis for Mutually Exclusive Binding of
mPER2 and FBXL3 to mCRY
Our mCRY1/mPER2 crystal structure explains why mPER2-
bound mCRY2 is completely devoid of FBXL3 in HEK293 cells
and a purified C-terminal mPER2 fragment displaces mCRY2
from FBXL3 (Xing et al., 2013) (Figure 4). Whereas mPER2 a3
blocks binding of the leucine-rich repeat (LRR) N domain of
FBXL3 to helix a22 and the sulfur loop of mCRY (Figure 4B,
left), the C-terminal mPER2 loop region, including the zincinterface, interferes with binding of the LRR C domain of
FBXL3 to mCRY a22 and the lid (Figure 4B, right). Moreover,
mPER2 a4 and a5 completely overlap with the conserved
mCRY2 C-terminal extension sequence (CCS), implying that
the CCS adopts a deviating orientation in the mCRY1/mPER2
complex (Figure 4B, right).
The high sequence identity (86%) and conservation of mCRY
binding residues between FBXL3 and FBXL21 (Hirano et al.,
2013; Yoo et al., 2013) suggest that these two counteracting
E3-ligase subunits bind to the same mCRY surface regions,
and therefore, simultaneous binding of FBXL21 and mPER2 is
unlikely, too.
Analyses of mCRY1-mPER2 Interactions In Vitro
To validate our mCRY1/mPER2 complex structure in solution
and to assess the relative contributions of the different interfaces
in vitro, we have generated mPER2[1119–1252] fragments with
point mutations in the mCRY1/mPER2 interfaces. Effects of
these mutations on the mCRY1-mPER2 interaction were
analyzed in pull-down assays using total lysates and in native
gels using purified proteins (Figures 5A, 5C, and 5D). The single
H1193E mutation in the mPER2(a4)-cap interface, which aims toCell 157, 1203–1215, May 22, 2014 ª2014 Elsevier Inc. 1207
Figure 4. mPER2 and FBXL3 LRR Are Mutually Exclusive in Binding to mCRY1/2
(A) Superposition of mCRY1 (cyan) in complex with mPER2 (yellow) and mCRY2 (green) in complex with FBXL3 LRR (leucine-rich repeat domain, light pink; PDB
ID 4I6J) (rmsd = 2.047 A˚ for 486 CRY Ca positions).
(B) Close-up view: mPER2[1132–1252] and FBXL3 LRR occupy partly overlapping binding sites on mCRY (CCS, conserved cryptochrome C-terminal extension
sequence).
See also Figure S3.electrostatically interfere with binding to the mCRY1 C-terminal
lid (Figure 2D), showed wild-type (WT)-like behavior in both
assays. However, in combination with the D1167R mutation in
the C-terminal helix interface (Figure 2A, right), the H1193E
mutation further weakens mCRY1 binding. Binding of mCRY1
was even more severely impaired through the additional
F1181R mutation, which also targets the interaction with the
mCRY1 C-terminal lid (Figure 2D). These results suggest that
both interfaces (C-terminal helix interface and mPER2(a4)-cap
interface) are of similar importance for complex formation
in vitro. In addition, our native gel analyses imply that the
mCRY1 tail is not required for mCRY1/mPER2 complex forma-
tion, as comparable results were gained with the mCRY1-PHR
and full-length mCRY1 (Figures 5C and 5D).
Mutation of the zinc-coordinating residues Cys1210 and
Cys1213 to alanine surprisingly did not compromise complex
formation in vitro, neither in the total lysate (natural presence of
zinc) nor in the purified system (supplied with zinc acetate)
(Figures 5A, 5C, and 5D). Furthermore, no difference in complex
formationwas observed forWTproteinswhether zincwas added
to the buffer or not (Figures 5C and 5D), implying that the zinc-
binding interface is of minor importance for complex formation
in vitro. Affinity measurements (isothermal titration calorimetry,
ITC) further support this result because a Kd in the lower nano-
molar range was observed for the mCRY1-mPER2 interaction
even in the absence of zinc ions (Figure 5B). However, zinc bind-
ing clearly stabilizes the purified mCRY1/mPER2 complex as
demonstrated by the higher melting temperature of the WT1208 Cell 157, 1203–1215, May 22, 2014 ª2014 Elsevier Inc.complex compared to the zinc-free mCRY1/mPER2(C1210A/
C1213A) mutant complex in our thermofluor experiments
(Figure 6A). Furthermore, ITC experiments revealed that the
WT mCRY1/mPER2 complex binds zinc ions with a nanomolar
affinity (Kd of 8 nM) (Figure 6B).
mCRY1-mPER2Heterodimer Interfaces Are Present in a
Cellular Context
To validate our mCRY1/mPER2 complex structure in a cellular
environment and in the context of full-length mCRY1 and
mPER2 proteins, we have tested mCRY1 interface mutants for
their effect on the stability of the mCRY1/mPER2 complex using
a luciferase complementation assay (Figures 7A and S5A). Full-
length mCRY1 and mPER2 (WT or mutants) were expressed as
fusion proteins with C- and N-terminal firefly luciferase frag-
ments in HEK293 cells (Czarna et al., 2013). mPER2-mCRY1
interactions lead to a functional luciferase whose activity was
measured in cell lysates.
The mCRY1 T149E mutation was designed to sterically and
electrostatically weaken interactions with mPER2 a4 (Figure 2D).
Consistent with our structure and the reported importance of
mPER2 helices a4 and a5 for mCRY-mPER interactions (Tomita
et al., 2010), the T149E mutation drastically reduced mPER2
binding.
Disruption of the interaction of mCRY1 a22 with mPER2 a3
(Q486R) and with the loop connecting mPER2 a5 with the zinc-
binding motif (K485D) (Figure 2A, K485D/Q486R double mutant)
drastically reducedmPER2 binding to below 10%. This confirms
Figure 5. Biochemical Analysis of mCRY1/mPER2 Interfaces
(A) Ni2+ pull-down from total cell lysates testing for interactions of N-terminally His-tagged WT and mutant mPER2[1119–1252] proteins with untagged mCRY1
[1–496]. Eluates were analyzed on a Coomassie-stained 18% SDS-PAA gel. Negative controls: lane 1, pull-down of mCRY1 with a noncircadian control protein;
lane 3, pull-down with plain beads.
(B) ITC profile for the interaction of mCRY1[1–496] andmPER2[1119–1252]. The binding event is exothermic. Top: time response of heat change upon addition of
ligand (mPER2). Bottom: best fit obtained with a single site-binding model (best c2 statistic), resulting in a 1:1 stoichiometry (n = 1.02). The approximate Kd for the
mCRY1-mPER2 interaction is 28 nM.
(C and D) Native gels (top) with purified proteins testing interactions of mPER2[1119–1252] (WT and mutants) with (C) mCRY1[1–496] (PHR) and (D) mCRY1
[1–606] (full length). Samples were also analyzed by SDS-PAGE (bottom).
See also Figure S1 and Table S2.the existence and importance of the combined C-terminal helix
interface in a cellular environment. The P319R mutation in the
mCRY1 sulfur loop should also weaken the interaction with
mPER2 a3 (Figure 2A). Whereas the P319Rmutation moderately
reduced binding in our luciferase complementation assay (this
study), the K485D single mutation reduced binding to 20%
(Czarna et al., 2013). This finding suggests that mCRY1 binding
to the mPER2 loop region (targeted by K485D) is more important
than the interaction with the long mPER2 helix a3 (targeted by
Q486R and P319R) in vivo.
A double mutation in the mPER2(a1–2)-mCRY1(a12) interface
(A328R/K329D) (Figure 2C) reduces mPER2 interactions byabout one half. We conclude that mPER2 helices a1 and a2
contribute to mCRY1 binding also in a cellular environment but
are not as important for complex stability as for example helix a4.
Zinc Binding and Adjacent Disulfide Bond Formation Are
Interdependent in a Cellular Context and In Vitro
To define potential roles of the zinc ion and the CRY1 Cys363-
Cys412 disulfide bridge in a cellular environment, we have
mutated the zinc-coordinating residues of mCRY1 (Cys414
and His473) and mPER2 (Cys1210 and Cys1213), as well as
Cys363 and Cys412 to alanine. Themutants were tested for their
effect on the stability of the mCRY1/mPER2 complex using aCell 157, 1203–1215, May 22, 2014 ª2014 Elsevier Inc. 1209
Figure 6. High-Affinity Zinc Binding Stabi-
lizes the mCRY1-mPER2 Complex
(A) Melting temperature determination by ther-
mofluor analysis of zinc-stabilized WT mCRY1
[1–496]/mPER2[1119–1252] complex in com-
parison with zinc-free mCRY1/mPER2(C1210A
C1213A) mutant complex.
(B) ITC profile of zinc binding to the mCRY1
[1–496]/mPER2[1119–1252] complex. The binding
event is exothermic. Top: time response of heat
change upon addition of the zinc ligand. Bottom:
best fit obtained with a single site-binding model
(best c2 statistic) results in a stoichiometry of n =
0.67, probably because not all complexes are
active in zinc binding. The approximate Kd for Zn
2+
binding to the mCRY1/mPER2 complex is 8 nM.
See also Figures S4, S6, and S7.luciferase complementation assay in HEK293 cells (Figures 7A
and S5A).
The mCRY1 single mutations C414A and H473A significantly
reduced mPER2 binding, with the C414A single mutation being
more effective. Furthermore, very weak interactions were
observed between the mPER2(C1210A/C1213A) double-mutant
protein and wild-type or C414A mutant mCRY1, indicating that
zinc coordination is of vital importance for the formation of a
stable complex between full-length mCRY1 and mPER2 in vivo.
C412A and C363A single mutations, which prevent formation
of the Cys412-Cys363 disulfide bridge, slightly enhanced
mPER2 binding in some of our luciferase complementation
assays yet behaved wild-type like in other experiments. We
propose that disruption of this disulfide bridge enhances
mPER2 binding by facilitating the observed conformational
changes of the mCRY1 lid (discussed above). The mild and
somewhat fluctuating impact of the C412A and C363A single
mutations on mPER2 binding probably depends on the redox
status and hence the extent of Cys412-Cys363 disulfide bridge
formation in the HEK293 cells.
To test whether mCRY1 exists in an oxidized form also in
living cells, we analyzed mCRY1 disulfide bridge formation in
HEK293 cells by N-Ethylmaleimide (NEM) and Maleimide-
PEG (MP) modification (Figure 7B). Indeed, we found increased
molecular weight forms of mCRY1 (CRY1-MP) only in lysates
that were dithiothreitol (DTT) treated before MP modification,
but not when lysates were either left untreated or when poten-
tial disulfide bridges were stabilized with H2O2. This indicates
that full-length mCRY1 also occurs in oxidized forms within
cells.
Quite surprisingly, the mCRY1 C414A/C412A and the C414A/
C363A double mutations only weakened mPER2 binding to
50% in our luciferase complementation assay (Figure 7A).
Furthermore, mCRY1 single- (C412A) or double (C412A/
C414A)-mutant proteins showed 50% binding activity toward
mPER2 proteins containing the C1210A/C1213A double
mutation. Hence, the C412A and C363A mutations partially
rescue the severe weakening of the mCRY1-mPER2 interaction
by the mCRY1 (C414A) and mPER2 (C1210A/C1213A)
mutations, suggesting that reduction of the Cys412-Cys363
disulfide bridge and the resulting increased flexibility of the1210 Cell 157, 1203–1215, May 22, 2014 ª2014 Elsevier Inc.mCRY1 C-terminal lid decrease the severity of disruption of
the zinc-binding site.
To further elucidate whether the mCRY1 Cys412-Cys363
disulfide bridge forms in dependence of zinc in the mCRY1/
mPER2 complex in vitro, we kept purified zinc-containing and
zinc-free mCRY1/mPER2 complexes under reducing or non-
reducing conditions and monitored the mCRY1 oxidation status
by mass spectrometry (MS) (Figure S6). The presence of zinc in
the complexes was analyzed in parallel by atomic absorption
spectroscopy (ICP-OES) (Figure S7). Under nonreducing condi-
tions, only a moderate amount of the putatively oxidized mCRY1
species (with the total mass reduced by 2 Da as expected for
the oxidation of a disulfide bridge) is observed in the zinc-bound
WT mCRY1/mPER2 complex (Figure S6A, middle). However, in
the zinc-free mCRY1/mPER2(C1210A/C1213A) mutant complex
(Figure S6B), as well as when the zinc ion is removed from the
WT complex through EDTA (Figure S6A, right), mCRY1 appears
almost completely oxidized. To test whether the mCRY1 oxida-
tion status is affected by disulfide bond formation between
Cys412 and Cys363, we mutated Cys412 to alanine. Indeed,
the C412A mutation substantially reduced mCRY1 oxidation in
the zinc-free mCRY1(C412A)/mPER2(C1210A/C1213A) mutant
complex (Figure S6C), indicating that Cys412 oxidation
accounts for a significant fraction of the MS peak CRYp1
assigned to oxidized mCRY1 protein. However, we also found
a moderate amount of putatively oxidized mCRY1 after aeration
in the C412A mutant, suggesting additional disulfide bond
formation (Figure S6C). Notably, the behavior of the purified
zinc-free mCRY1(C412A)/mPER2(C1210A/C1213A) complex
mirrors that of theWTmCRY1/mPER2 complex in ourMS exper-
iments (Figure S6D). This observation is consistent with the
partial rescue of zinc-binding deficiency by the C412A and
C363A mutations observed in our luciferase complementation
experiment (Figure 7A).
In conclusion, our mutational analyses confirm the presence
of all heterodimer interfaces revealed by our mCRY1/mPER2
crystal structure and indicate an interdependent role of the
coordinated zinc ion and of the mCRY1 Cys412-Cys363 disul-
fide bridge, among others, in the positive (zinc) and negative
(disulfide bridge) regulation of the mCRY1-mPER2 interaction
in vivo.
AB C D
Figure 7. mCRY1/mPER2 Complex Formation Is Regulated by Four Interfaces, a Zinc Ion, and Disulfide Bridge Formation in Living Cells
(A) Luciferase complementation assay. All heterodimer interfaces revealed by the crystal structure are present in full-length mCRY1/mPER2 complexes inside
cells. Disruption of the zinc interface is partially rescued by mutation of the disulfide bond forming Cys363 and Cys412. Full-length mCRY1 and mPER2 (WT or
mutants) were expressed as fusion proteins with firefly luciferase fragments in HEK293 cells (Czarna et al., 2013). Approximately equal expression of fusion
proteins was detected in western blot experiments (Figure S5A). Data are normalized to renilla luciferase activity (used as a transfection control) and presented
relative to mCRY1(WT)-mPER2(WT) activity. Shown are mean ± SEM of three (left) or four (right) independent transfections. Three additional experiments gave
similar results.
(B) mCRY1 forms disulfide bridges in living cells: HEK293 cells transiently transfected with mCRY1 were harvested in presence of excess amounts of
N-Ethylmaleimide (NEM) that immediately block all free thiol groups. Subsequently, disulfide bridges were reduced with Dithiothreitol (+DTT), and any thiol group
previously oxidized was now modified with Maleimide-PEG (MP, MW 5 kDa). Increased molecular-weight forms of mCRY1 were detected in cell lysates treated
with DTT, but not when lysates were not reduced (DTT) or even oxidized with H2O2. This indicates that, within cells, full-length mCRY1 can occur in oxidized
forms with one or more disulfide bridges.
(C) Critical cysteine residues coordinate zinc in the mCRY1/mPER2 complex in a cellular context: HEK293 cells were transiently transfected with full-length
mPER2 or mCRY1 either as WT versions or with alanine mutations in the zinc-coordinating Cys414 (mCRY1), Cys1210, and Cys1213 (mPER2), as well as the
disulfide bond forming Cys412 of mCRY1. Immunoprecipitated mPER2 was incubated with mCRY1-containing cell lysate in the presence of the radioactive zinc
isotope 65Zn2+. In this pull-down assay,WT proteins incorporated significantly (t test) more 65Zn2+ than themutants. Shown aremean ±SEMof three independent
immunoprecipitation experiments. The high expression of proteins was verified in western blot experiments (not shown).
(D) Zinc ions enhance themCRY1-mPER2 interaction in living cells: TwoU2-OS reporter cell lines, which stably expressmCRY1 andmPER2 split luciferase fusion
proteins either as WT or with alanine mutations in the zinc-coordinating cysteins (Cys414 of mCRY1; Cys1210, Cys1213 of mPER2) and Cys412 of mCRY1 (mut:
C412A/C414A/C1210A/C1213A), were cultivated in Zn2+-depleted medium for about a week. Then various concentrations of Zn2+ were added to the medium
while continuously monitoring luciferase activity. Treatment with zinc ions (but not iron ions, not shown) dose-dependently increases luciferase activity in cells
expressing WT mCRY1 and mPER2 (see also Figure S5C), but not or to a much lesser extent in cells expressing mCRY1 and mPER2 with mutations of zinc-
coordinating residues. Zinc has no effect on mRNA expression levels of the reporter constructs (not shown) or on luciferase activity of a control U2-OS cell
expressing mCRY1-LUCIFERASE (not shown). Shown are mean ± SEM of four independent treatments. Several additional experiments gave similar results.
See also Figures S1, S2, and S5.Zinc Ions Bind to the mCRY1/mPER2 Complex in a
Cellular Context and Enhance the mCRY1-mPER2
Interaction in Living Cells
To test whether zinc can bind to the mCRY1/mPER2 complex
in a cellular environment, we transiently transfected HEK293
cells with full-length mPER2 or full-length mCRY1 either as WT
versions or with mutations in the three zinc-coordinating cyste-
ines (mCRY1: C414A; mPER2: C1210A and C1213A) and the
disulfide bridge forming Cys412 of mCRY1. To ensure that
sufficiently stable mCRY1/mPER2 complexes are formed even
without zinc coordination, we used the mCRY1 (C412A andC414A) double mutant, which enhanced mCRY1-mPER2 inter-
action compared to the C414A single mutation in our luciferase
complementation assays (Figure 7A). Immunoprecipitated
mPER2 was incubated with mCRY1-containing cell lysate in
the presence of the radioactive zinc isotope 65Zn2+. A 7-fold
increase in 65Zn2+ radioactivity was detected when mPER2-
and mCRY1-containing cell lysates were used. Mutations in
the zinc coordination site led to a substantial and significant
reduction of zinc binding (Figure 7C). In addition, immunoprecip-
itated mPER2 incubated with a control lysate did essentially not
incorporate 65Zn2+ (Figure S5B). Together, these results indicateCell 157, 1203–1215, May 22, 2014 ª2014 Elsevier Inc. 1211
that zinc can bind to the full-length mCRY1/mPER2 complex in a
cellular context, and this binding depends on critical zinc-coor-
dinating cysteine residues in both proteins. The residual radioac-
tivity observed for the mutant proteins could be due to 65Zn2+
binding to large endogenous mCRY1/mPER2 complexes re-
cruited via mPER PAS domain homodimer interactions (Kucera
et al., 2012), as well as unspecific zinc binding.
To investigate whether zinc ions also contribute to the stabili-
zation of the mCRY1-mPER2 interaction in living cells, we
created two reporter U2-OS cell lines that stably express
mPER2 and mCRY1 split luciferase fusion proteins either as
WT proteins or with mutations in the zinc-coordinating residues
Cys414 (mCRY1), Cys1210, and Cys1213 (mPER2), as well as
the disulfide bridge forming Cys412 of mCRY1 (mut: C412A/
C414A/C1210A/C1213A). Treatment with zinc (but not iron)
ions dose-dependently enhances the bioluminescence in cells
expressing WT mPER2 and mCRY1, but not or to a much lesser
extent in cells expressing mutant mCRY1 and mPER2 proteins,
indicating that zinc coordination indeed contributes to mCRY1-
mPER2 interaction strength, and this effect depends on the
integrity of the zinc-coordinating residues (Figures 7D and S5C).
DISCUSSION
Our crystal structure of the mCRY1/mPER2 heterodimer shows
an intimate and high-affinity clock protein complex with a zinc
interface that critically stabilizes the mCRY1/mPER2 complex
in mammalian cells. Our cell-based and in vitro (LC-ESI-MS/
ICP-OES) studies suggest that the coordinated zinc ion struc-
turally facilitates the reduction of a nearby located disulfide
bridge of mCRY1 (probably between Cys412 and Cys363,
among others), which likely enhances the flexibility of the
mCRY1 C-terminal lid and thereby mPER2 binding. This func-
tionally important interplay between an intermolecular compos-
ite 3Cys/1His zinc-binding site in a heterodimer interface and
one or more intramolecular disulfide bonds formed by nearby
located cysteine residues has not been observed in other
zinc-binding proteins (e.g., Maret, 2012; Auld, 2001). Notably,
the redox-regulated chaperone Hsp33 and anti-s factor RsrA
use intramolecular cysteine-containing zinc centers as redox
sensors (Ilbert et al., 2006). In both proteins, oxidative or disul-
fide stress leads to oxidation and, hence, disulfide bond forma-
tion of their zinc-coordinating cysteines, as well as zinc release,
which induce conformational changes leading to their func-
tional activation. On the other hand, betaine-homocysteine
methyltransferase is reversibly inactivated through oxidation
of its zinc-coordinating cysteines and zinc release (Evans
et al., 2002).
Our LC-ESI-MS/ICP-OES experiments show that the mCRY1/
mPER2 complex does not release its zinc ion under nonreducing
conditions (Figure S7, number 2). Instead, the experiments
suggest that zinc release supports mCRY1 oxidation (Figures
S6A, top right, and S6B) and that this oxidation also involves
Cys412 (Figure S6C). Using the same basic elements (i.e., a
zinc ion and a nearby located highly reactive cysteine) but in a
different structural arrangement, mode of action, and interplay,
the CRY1/PER2 complex therefore may act as a sensor of the
rhythmically changing redox state of the cell, which was1212 Cell 157, 1203–1215, May 22, 2014 ª2014 Elsevier Inc.proposed to be involved in driving circadian rhythms (Edgar
et al., 2012; O’Neill and Reddy, 2011; O’Neill et al., 2011;
Wang et al., 2012).
In general, there are various intracellular zinc pools
described such as zinc in vesicles, zinc tightly bound to mac-
romolecules, zinc bound to metallothioneins (the major cellular
zinc storage proteins), and a pool of ‘‘free’’ zinc (Oteiza, 2012).
Although the total cellular amount of zinc is described to be in
the high micromolar range, the concentration of ‘‘free’’ zinc is
much lower (nano- to picomolar) because most zinc is bound
to proteins with high affinity. However, under certain circum-
stances, e.g., oxidative stress, zinc may be released. Our
measured Kd for zinc binding to the mCRY1/mPER2 complex
in the lower nanomolar range suggests a dynamic, regulatory
zinc-binding site that might be influenced by its environment
within the cell.
Interestingly, the zinc-coordinating residues and most other
residues mediating CRY-PER interactions are conserved in
vertebrate CRY and PER2 proteins, in PER1, and, to a minor
extent, in PER3, which strongly suggests the existence of homo-
logous CRY/PER complexes (Figures S1 and S2).
Lacking the knowledge about the mCRY1-mPER2 zinc inter-
face, Okano et al. (2009) generated a transgenic mouse line
constitutively overexpressing mCRY1 with a C414A mutation.
These mice showed a long 28 hr free-running period of loco-
motor activity rhythms and abnormal entrainment behavior, as
well as symptoms of diabetes, including reduced b cell prolifer-
ation and insulin secretion (hypoinsulinemia) (Okano et al., 2009,
2010, 2013). Most likely, these dominant in vivo effects of the
C414A mutation are due to disruption of the mCRY1-mPER2
zinc interface, demonstrating the importance of zinc-dependent
mCRY1/mPER2 complex formation for circadian dynamics
and metabolic regulation. Notably, mutations in mBMAL1 and
mCLOCK also lead to hypoinsulinemia and defective b cell
function, whereas mCRY1/mCRY2 double-knockout mice
exhibit hyperinsulinemia and tissue-specific insulin resistance
(Barclay et al., 2013; Marcheva et al., 2010). Furthermore, the
mCLOCKD19 mutation leads to extended circadian periods,
whereas mCry1/ mice exhibit a period shortened by 1 hr
(King et al., 1997; van der Horst et al., 1999). Hence, the circadian
and metabolic phenotypes of the mCRY1 C414A mutation are
more similar to those resulting from mutations in the mCLOCK/
BMAL1 complex than to mCRY knockouts. Our structure sug-
gests that the intimate interaction of mPER2 with mCRY1 a22
interferes with repressive mCRY1 binding to the mCLOCK/
BMAL1-E-box complex. Thus, we speculate that the weakened
mPER2 interaction of the zinc-binding-deficient mCRY1(C414A)
mutant protein (Figure 7A) leads to an enhanced transcriptional
repression activity in vivo. We further propose that, in trans-
genic mice, the overexpressed mCRY1(C414A) mutant protein
represses the mCLOCK/BMAL1 complex more strongly than
endogenous WT mCRY1. This may cause the dominant pheno-
type of the mCRY1(C414A) mutation, which somewhat resem-
bles the phenotypes of transgenic mice expressing weakened
transcriptional activator complexes, including, for example, the
mCLOCKD19 mutant protein.
Our structure also shows that binding of FBXL3 or PER2
to CRY is mutually exclusive and suggests that PER2 stabilizes
CRY1 by shielding it from FBXL3. Strikingly, neither mPER2
(this study) nor FBXL3 (Xing et al., 2013) binds in close proximity
of the AMPK phosphorylation site Ser71, suggesting that
AMPK regulates PER2 and FBXL3 binding in a more indirect
manner. Notably, Cys412 appears highly reactive in switching
functions because it not only forms the intramolecular disulfide
bond to Cys363 in apo-mCRY1 but also an intermolecular disul-
fide bond with FBXL3 in the CRY2/FBXL3 complex structure.
Taken together, our crystal structure provides a more
complete understanding of how mammalian CRY and PER
proteins interact, how this interaction might be sensing and be
regulated by cellular redox/metabolic states, and how the inter-
play with other clock components drives the circadian clock and
metabolic processes. This will guide the design of new mutants,
experiments, and small-molecule ligands to study or target
macromolecular CRY/PER containing complexes in vivo.
EXPERIMENTAL PROCEDURES
Protein Purification and Crystallization
mCRY1 and mPER2 proteins were recombinantly expressed as His-fusions
in insect cells and E. coli, respectively. For purification of the mCRY1/
mPER2 complex (native and selenomethionine labeled), lysates were
combined and copurified via Ni2+ affinity, anion exchange, and heparin and
size-exclusion chromatography columns. For biochemical analysis, mCRY1
proteinswere purified via Ni2+ affinity, anion exchange, heparin and size-exclu-
sion columns, mPER2 proteins via Ni2+ affinity followed by tag cleavage, anion
exchange, and size-exclusion chromatography.
Crystals of the mCRY1/mPER2 complex grew at 20C in 0.2 M MgCl2 and
12%–13% PEG3350. They contain one complex per asymmetric unit (space
group P43212).
Data Collection, Structure Determination, and Refinement
A 2.45 A˚ data set of a mCRY1/mPER2 crystal and a 2.8 A˚ data set of a seleno-
methione-labeled mCRY1/mPER2 crystal were collected at beamline PXII
(SLS). The mCRY1/mPER2 complex structure was solved by molecular
replacement with apo-mCRY1 (PDB ID 4K0R) as search model combined
with selenium single-wavelength anomalous dispersion (SAD) phasing. Data
collection and refinement statistics are summarized in Table S1.
Inductively Coupled Plasma Optical Emission Spectrometry
We performed inductively coupled plasma optical emission spectrometry
(ICP-OES) using a Varian VISTA-RL spectrometer with a MicroMist nebulizer.
Zinc binding was determined by measuring its specific emission at
213.857 nm.
Pull-Down Experiments
Clear lysates of E. coli cells expressing His-tagged mPER2 (WT and mutants)
were incubated with Ni-Sepharose 6 Fast Flow beads in presence of 25 mM
imidazole for 1 hr. After washing and equilibration in lysis buffer with 70 mM
imidazole, mPER2-boundNi-beadswere incubated with clear lysates of insect
cells expressing untagged mCRY1 for 1 hr in order to pull down mCRY1. The
beads were extensively washed before elution of the bound complex with
500 mM imidazole and analysis by SDS-PAGE.
Native PAGE Analysis
Purified proteins were incubated at a 1:1 molar ratio in a BIS-Tris Propane
buffer (pH 7.0) at 4C for at least 2 hr. Samples were analyzed on a native
4%–20% Novex Tris-Glycine gel and by SDS-PAGE.
Circular Dichroism, Isothermal Titration Calorimetry, and
Thermofluor
Circular dichroism (CD) spectroscopy using a Jasco J-810 spectropolarimeter
and ITC experiments using a VP-ITCMicroCalorimeter were performed essen-tially as described in Czarna et al. (2011). Thermofluor was performed as
described in Weir et al. (2010).
LC-ESI MS Analysis
PurifiedWT and mutant mCRY1/mPER2 complexes were kept under reducing
(4 mM DTT) or nonreducing (no DTT, aeration) conditions for 2 days. For
removal of bound zinc, the protein complex was treated with 10 mM EDTA,
and zinc-bound EDTA was removed by dialysis. LC-MS analyses were per-
formed on a Bruker micrOTOF connected to an Agilent 1100 HPLC system
equipped with a diode array detector.
Luciferase Complementation Assay
The luciferase complementation assay was performed essentially as
described in Kucera et al. (2012).
Analysis of Disulfide Bridges in mCRY1
mCRY1 disulfide bridges were analyzed essentially using a combined method
fromWu et al. (2000) and Templeton et al. ( 2010). Free thiol groups in lysates of
MYC-tagged mCRY1-expressing HEK293 cells were blocked with 50 mM
NEM, excess NEM was removed by methanol precipitation, and disulfide
bridges were then reducedwith 20mMDTT. After removal of DTT bymethanol
precipitation, arosen free thiol groups were modified by incubation with
300 mM Maleimide-PEG. Samples were then analyzed by western blotting
using an anti-MYC antibody.
Live-Cell Zinc-Binding Assay
Human U2-OS cells stably expressing mCRY1 and mPER2 as split-luciferase
hybrid proteins were kept for at least 1 week in zinc-depleted medium prior to
zinc ion addition. Bioluminescence of reconstituted luciferase was recorded
for several days.
65Zn-Binding Assay
HEK293 cells were cultured for 5 days in zinc-free medium before transfection
with equal amounts of plasmid DNA encoding either WT or mutant epitope-
tagged mCRY1 or mPER2. Lysates with overexpressed V5-tagged mPER2
constructs were incubated with anti-V5 antibody and equivalent amounts of
Protein G PLUS-agarose beads overnight. Beads were washed, mixed with
lysates overexpressing mCRY1 or control lysates, and incubated for 3 hr
with 35 mM 65ZnCl2 radionuclide at room temperature. After washing,
65Zn
binding was determined by scintillation counting in a Wallac 1440 DSA
system.
The Extended Experimental Procedures section, which provides detailed
information about all experimental procedures, including protein purification,
crystallization, structure determination, in vitro interaction studies (ITC, native
gels, and pull-down), circular dichroism, thermofluor, LC-ESI-MS, and atomic
absorption spectroscopy (ICP-OES), as well as cell-based studies (luciferase
complementation assays, zinc-binding assays, and disulfide bond formation),
is included in the Supplemental Information.
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